INFORMATION ON THIS SITE IS ONLY INTENDED FOR NON-US USERS
Obesity
A chronic disease with very limited options for adolescents[1,2]
1st prescription medication approved in adolescents with obesity[1]
4x
Patients were 4 times more likely with Saxenda® to achieve a ≥10% BMI reduction than with placebo4
2.4%
Only 2.4% of patients on Saxenda® experienced serious adverse events (compared with 4% on placebo)4
-0.22
Difference in BMI SDS between Saxenda® and placebo at 56 weeks4
Cardel MI, Jastreboff AM, Kelly AS. Treatment of adolescent obesity in 2020. JAMA. 2019;322(17):1707-1708.
Farpour-Lambert NJ, Baker JL, Hassapidou M, et al. Childhood obesity is a chronic disease demanding specific health care—a position statement from the Childhood Obesity Task Force (COTF) of the European Association for the Study of Obesity (EASO). Obes Facts. 2015;8(5):342-349.
Lifshitz F. Obesity in children. J Clin Res Ped Endo. 2008;1(2):53-60.
Saxenda® [summary of product characteristics]. Bagsværd, Denmark: Novo Nordisk A/S; June-2021.
Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117-2128.